|
Press Releases |
|
 |
|
Wednesday, June 23, 2021 |
|
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma |
Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide) in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable). more info >> |
|
Friday, June 18, 2021 |
|
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate |
Eisai Co., Ltd. and Bristol-Myers Squibb Company announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). more info >> |
|
Tuesday, June 15, 2021 |
|
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma |
Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) in Europe, the Middle East, Russia, and Australia to Advanz Pharma. more info >> |
|
Wednesday, June 9, 2021 |
|
Eisai Receives Special Prize at Platinum Career Award 2021 |
Eisai Co., Ltd. announced today that it has received a special prize at the Platinum Career Award 2021. The awards ceremony was held via online at the symposium on June 8, 2021. more info >> |
|
Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021) |
Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021. more info >> |
|
Tuesday, June 8, 2021 |
|
Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM |
Following U.S. Food and Drug Administration's (FDA) accelerated approval of ADUHELMTM (aducanumab-avwa) as the first and only Alzheimer's disease treatment to address a defining pathology of the diseas. more info >> |
|
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's disease treatment to address a defining pathology of the disease |
Biogen and Eisai, Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM (aducanumab-avwa) as the first and only Alzheimer's disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. more info >> |
|
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib |
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. announced new investigational data from the pivotal Phase 3 CLEAR(Study 307)/KEYNOTE-581 trial, which evaluated the combinations of LENVIMA. more info >> |
|
Monday, May 31, 2021 |
|
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia |
Eisai Co., Ltd. and ITO EN, LTD. announced today that both parties have entered into a business alliance agreement concerning the initiatives for supporting people living with and preventing dementia with the aim of realizing a healthy and long-lived society. more info >> |
|
Thursday, May 20, 2021 |
|
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting |
Eisai Co., Ltd. announced today that the latest data regarding its oncology pipeline and products including in-house discovered lenvatinib mesylate and eribulin mesylate will be presented at the American Society of Clinical Oncology (2021 ASCO Annual Meeting*), to be held virtually from June 4 to 8, 2021. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
SMBC and Fujitsu partner towards creation of AI-powered data analytics business
Apr 3, 2025 22:10 JST
|
|
|
AI Paradox in QA: Twice as Many Testers Fear Job Loss, But Adoption Keeps Climbing
Apr 3, 2025 20:06 HKT/SGT
|
|
|
The India Market Entry Dilemma: What's Holding Manufacturers Back
Apr 3, 2025 19:30 HKT/SGT
|
|
|
Connect Marketplace Hong Kong 2025 Concludes Successfully
Apr 3, 2025 18:29 HKT/SGT
|
|
|
JBM Healthcare Completes Acquisition of 90% Interest in Tin Hee Tong
Apr 3, 2025 17:30 HKT/SGT
|
|
|
Guinean Artist Elie Kamano to Release New Single Exploring Africa's Colonial Past
Apr 3, 2025 17:00 HKT/SGT
|
|
|
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025
Apr 3, 2025 17:00 HKT/SGT
|
|
|
Asiaray Achieves Net Profit Turnaround of RMB10.4 Million in 2024
Apr 3, 2025 16:41 HKT/SGT
|
|
|
JF SmartInvest Holdings Ltd Announces 2024 Annual Results
Apr 3, 2025 15:59 HKT/SGT
|
|
|
AEON CREDIT SERVICE (ASIA) COMPANY LIMITED FY2024/25 Revenue Up to HK$1,759.3 million with Net Profit of HK$400.5 million
Apr 3, 2025 14:04 HKT/SGT
|
|
|
Prideone Entertainment Announces New Post-War Film to Commemorate the 80th Anniversary of World War II's End
Apr 3, 2025 7:00 JST
|
|
|
3rd Future Cross Border Payments Summit, Dubai 2025: Trends Shaping the Future of Payments
Apr 2, 2025 22:03 HKT/SGT
|
|
|
Doubleview Gold Corp 2025 Exploration Program
Apr 2, 2025 21:00 HKT/SGT
|
|
|
Hola Prime Launches Industry-First One-on-One Mentorship from Market Experts
Apr 2, 2025 20:00 HKT/SGT
|
|
|
Innovation Beverage Group Expands U.S. Distribution of its Award-Winning Bitters Through One of the Nation's Largest Beverage Alcohol Distributors
Apr 2, 2025 19:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|